These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26692928)

  • 1. Matrine increases NKG2D ligand ULBP2 in K562 cells via inhibiting JAK/STAT3 pathway: a potential mechanism underlying the immunotherapy of matrine in leukemia.
    Lu X; Zhu Z; Jiang L; Sun X; Jia Z; Qian S; Li J; Ma L
    Am J Transl Res; 2015; 7(10):1838-49. PubMed ID: 26692928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Up-regulation of NKG2D ligand ULBP2 by matrine in K562 cells and the underlying molecular mechanisms].
    Ma L; Zhu Z; Lu X; Jiang L; Zhou M; Qian S; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2014 May; 35(5):438-42. PubMed ID: 24857216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Growth inhibition effect of matrine on K562 cells mediated by IL-6/JAK/STAT3 signaling pathway].
    Ma L; Zhu Z; Sun X; Jiang L; Bai Y; Lu X; Zhou M; Qian S; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):422-6. PubMed ID: 26031532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrine regulates immune functions to inhibit the proliferation of leukemic cells.
    Zhang L; Zhang H; Zhu Z; Jiang L; Lu X; Zhou M; Sun X; He L; Bai Y; Ma L
    Int J Clin Exp Med; 2015; 8(4):5591-600. PubMed ID: 26131142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of matrine on the expression of NKG2D ligands in leukemia cells].
    Ma LD; Lu XZ; Zhu ZC; Jiang LJ; Zhou M; Qian SX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1429-34. PubMed ID: 24370024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrine inhibits BCR/ABL mediated ERK/MAPK pathway in human leukemia cells.
    Ma L; Xu Z; Wang J; Zhu Z; Lin G; Jiang L; Lu X; Zou C
    Oncotarget; 2017 Dec; 8(65):108880-108889. PubMed ID: 29312576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 contributes to NK cell recognition by modulating expression of NKG2D ligands in adriamycin-resistant K562/AO2 cells.
    Cai X; Lu X; Jia Z; Zhang X; Han W; Rong X; Ma L; Zhou M; Chen B
    Int J Hematol; 2015 Nov; 102(5):536-43. PubMed ID: 26387089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells.
    Zhu Z; Lu X; Jiang L; Sun X; Zhou H; Jia Z; Zhang X; Ma L
    Am J Transl Res; 2015; 7(10):1896-907. PubMed ID: 26692933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of Anti Apoptosis and Immune Evasion in Drug-Resistant Leukemia Cells Mediated by STAT3].
    Jia ZX; Lu XZ; He JY; Cai XH; Qin W; Han WM; Zhou M; Xu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1796-1803. PubMed ID: 33283701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.
    Kimura M; Nagashima H; Okuyama Y; Ishii N; So T
    Int Immunol; 2018 Jun; 30(7):291-299. PubMed ID: 29668931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Chidamide on the Killing Acitivity of NK Cells Targeting K562 Cells and Its Related Mechanism In Vitro].
    Weng LY; Xue L; He CX; Xu QW; Chu CY; Wang YM; Wang XB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1167-1170. PubMed ID: 32798393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart.
    Pan J; Fukuda K; Kodama H; Sano M; Takahashi T; Makino S; Kato T; Manabe T; Hori S; Ogawa S
    Heart Vessels; 1998; 13(4):199-208. PubMed ID: 10442402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of humanized interleukin 21 on anti-leukemic activity of cytokine induced killer cells and the mechanism].
    Zhao N; Zhao MF; Rajbhandary S; Lu WY; Zhu HB; Xiao X; Deng Q; Li YM
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):823-8. PubMed ID: 23384903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway.
    Yang H; Zhang J; Li J; Zhao F; Shen Y; Xing X
    Exp Ther Med; 2018 Nov; 16(5):4296-4302. PubMed ID: 30344703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways.
    Rajbhandary S; Zhao MF; Zhao N; Lu WY; Zhu HB; Xiao X; Deng Q; Li YM
    Asian Pac J Cancer Prev; 2013; 14(10):5825-31. PubMed ID: 24289584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells.
    Song H; Kim KE; Hur D; Lim JS; Yang Y; Cho BJ; Kim CH; Kim T; Bang S; Lee WJ; Park H; Cho D
    Immunol Lett; 2008 Oct; 120(1-2):103-7. PubMed ID: 18706445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.